SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK
31.54
08-May-25 16:00:14
15 minutes delayed
Stocks
+0.60
+1.94%
Today's range
30.44 - 31.91
ISIN
N/A
Source
NASDAQ
-
Supernus to Host First Quarter 2021 Financial Results Conference Call
27 Apr 2021 17:44:01 By Nasdaq GlobeNewswire
-
Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD
02 Apr 2021 16:58:32 By Nasdaq GlobeNewswire
-
Supernus to Present at Cowen Healthcare Conference
26 Feb 2021 09:00:00 By Nasdaq GlobeNewswire
-
Supernus Announces Fourth Quarter and Full Year 2020 Financial Results
25 Feb 2021 16:00:00 By Nasdaq GlobeNewswire
-
Supernus to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call
23 Feb 2021 09:00:00 By Nasdaq GlobeNewswire
-
Supernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients
08 Feb 2021 09:00:00 By Nasdaq GlobeNewswire
-
Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference
06 Jan 2021 17:29:08 By Nasdaq GlobeNewswire